Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The universal influenza vaccine (Changchun BCHT Pharmaceutical) is a preclinical vaccine candidate designed to provide broad and durable protection against a wide range of influenza virus strains. Developed by Changchun BCHT Pharmaceutical, this vaccine aims to overcome the limitations of traditional seasonal influenza vaccines, which require annual updates due to antigenic drift. By targeting conserved regions of the influenza virus that are less prone to mutation, the vaccine is intended to elicit an immune response effective against multiple subtypes and lineages of Influenza A and B, potentially offering long-term protection against both seasonal and pandemic strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on universal influenza vaccine (Changchun BCHT Pharmaceutical).